[
    "ine, thapsigargin and a compound of formula (I):</p><img id=\"EMI-C00001\" path=\"US20120108553A1-20120503-C00001.TIF\" file=\"https://surechembl.org/api/assets/attachment/193924270/US/20120503/A1/020120/10/85/53/US20120108553A1-20120503-C00001.TIF\"/></p>wherein n is 0 or 1; R<sup>5 </sup>is H, F or Cl; R<sup>6 </sup>is azido, \u2014C(O)CHN<sub>2</sub>, \u2014N(H)C(O)NH<sub>2</sub>, \u2014N(H)C(O)H, \u2014C(O)R or the following 5-membered heterocycle:</p><img id=\"EMI-C00002\" path=\"US20120108553A1-20120503-C00002.TIF\" file=\"https://surechembl.org/api/assets/attachment/193924272/US/20120503/A1/020120/10/85/53/US20120108553A1-20120503-C00002.TIF\"/></p>wherein R is NR<sup>2</sup>R<sup>3 </sup>or OR<sup>4</sup>; R<sup>2 </sup>and R<sup>4 </sup>each, independently, are hydrogen or C<sub>1-4</sub>alkyl; R<sup>3 </sup>is hydrogen, C<sub>1-4 </sub>alkyl or CH<sub>2</sub>OH; W and Z are, independently, C(H) or N; A is O, S or NH; and X<sup>\u2212</sup> is a physiologically suitable counter-anion.\u201d</p>In another embodiment, the prostaglandin mimetic is a prostacyclin mimetic. In yet another embodiment, the prostaglandin mimetic is a prostaglandin agonist. In still another embodiment, prostaglandin agonist is selected from a PGI<sub>2 </sub>agonist or a PGE<sub>2 </sub>agonist. In another embodiment, the agonist is selected from the group consisting of U46619, I-BOP, STA<sub>2</sub>, BW245C, L-644698, ZK110841, 13,15-dihydro-15-keto-PGD<sub>2</sub>, indomethacin, 15-R-methyl-PGD<sub>2</sub>, 15d-PGJ<sub>2</sub>, ONO-KI-004, iloprost, 17-phenyl-trinor PGE<sub>2</sub>, sulprostone, butaprost, 11-deoxy PGE<sub>1</sub>, AH13205, ONO-AEI-259, sulprostone, MB28767, misoprostol, SC46275, ONO-AE-249, PGE<sub>1</sub>-OH, ONO-AEI-329, cicaprost, carbacyclin, fluprostenol, latanoprost, travoprost, bimatoprost, beraprost, cloprostenol sodium, eicosopentanoic acid, docosohexanoic acid, ceramide, sodium butyrate and aluminum fluoride.</p>In another embodiment, the invention provides use of the pharmaceutical composition of the invention, for the treatment or prevention of deleterious effects associated with NSAID administration in a subject. In one embodiment, the deleterious effects associated with NSAID administration in a subject is related to a decrease in one or more prostaglandins anywhere in the gastrointestinal tract. In another embodiment, the deleterious effects associated with NSAID administration in a subject is related to a decrease in one or more prostaglandins in the stomach. In still another embodiment, the prostaglandins are PGE<sub>2 </sub>and/or PGI<sub>2</sub>. In another embodiment, the deleterious effect associated with NSAID administration in a subject is GI toxicity. In yet another embodiment, the GI toxicity is selected from the group consisting of gastritis, peptic erosions, ulceration, gastric lesions and GI bleeds.</p>In another embodiment, the NSAID for use in the invention is selected from the group consisting of aspirin, indomethacin, voltaren, naprosyn, ibuprofen, napro",
    "fen, tolmetin, sulindac, meclofenamate, ketoprofen, piroxicam, flurbiprofen, diclofenac, acetylsalicylic acid, sodium acetylsalicylic acid, calcium acetylsalicylic acid, salicylic acid, sodium salicylate, choline salicylate, magnesium salicylate, salsalate, sodium salicylate, diflunisal, ketorolac, carprofen, mefenamic acid, meloxicam and nimesulide.</p>In another aspect, the invention provides a method of treating pain and/or inflammation in a subject, said method comprising administering to the subject in need thereof a therapeutically-effective amount of a pharmaceutical composition comprising an NSAID and a molecule that selectively stimulates the release of a prostaglandin. In one embodiment, the molecule is selected from the group consisting of genistein, daidzein, tamoxifen, tetrandrine, thapsigargin and a compound of formula (I).</p>In another aspect, the invention provides a method of treating pain and/or inflammation in a subject, said method comprising administering to the subject in need thereof a therapeutically-effective amount of a pharmaceutical composition comprising an NSAID and a prostaglandin agonist. In one embodiment, the prostaglandin agonist is selected from a PGI<sub>2 </sub>agonist or a PGE<sub>2 </sub>agonist. In another embodiment, the agonist is selected from the group consisting of U46619, I-BOP, STA<sub>2</sub>, BW245C, L-644698, ZK110841, 13,15-dihydro-15-keto-PGD<sub>2</sub>, indomethacin, 15-R-methyl-PGD<sub>2</sub>, 15d-PGJ<sub>2</sub>, ONO-KI-004, iloprost, 17-phenyl-trinor PGE<sub>2</sub>, sulprostone, butaprost, 11-deoxy PGE<sub>1</sub>, AH13205, ONO-AEI-259, sulprostone, MB28767, misoprostol, SC46275, ONO-AE-249, PGE<sub>1</sub>-OH, ONO-AEI-329, cicaprost, carbacyclin, fluprostenol, latanoprost, travoprost, bimatoprost, beraprost, cloprostenol sodium, eicosopentanoic acid, docosohexanoic acid, ceramide, sodium butyrate and aluminum fluoride. In another embodiment, the inflammation is selected from the group consisting of fever, arthritis, asthma, bronchitis, menstrual cramps, tendinitis, bursitis, inflammatory disorders of the skin, gastrointestinal conditions, vascular diseases, migraine headaches, periarteritis nodosa, thyroidiris, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, myasthenia gravis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, hypersensitivity, conjunctivitis, gingivitis, swelling occurring after injury and myocardial ischemia. In yet another embodiment, the arthritis is selected from rheumatoid arthritis, spondyloarthopathies, gouty arthritis, systemic lupus erythematosus, osteoarthritis and juvenile arthritis. In still another embodiment, the inflammatory disorders of the skin are selected from the group consisting of psoriasis, eczema, burns and dermatitis. In another embodiment, the gastrointestinal conditions are selected from the group consisting of inflammatory bowel syndrome, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative col",
    "ciprofibrate.</p>Prostaglandin agonist compounds include natural prostaglandins such as PGI2, PGD<sub>1</sub>, PGD<sub>2</sub>, PGE<sub>2</sub>, PGE<sub>1</sub>, PGF<sub>2 </sub>and PGF-<sub>2</sub>\u03b1, and analogs of the natural prostaglandins, including compounds that bind to PPAR, the PGI<sub>2 </sub>receptor UP), the PGE<sub>2 </sub>receptors (EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3 </sub>and EP<sub>4</sub>), the TXA<sub>2 </sub>receptor (TP), the PGD<sub>2 </sub>receptors (DP and CRTH2) and the PGF<sub>2</sub>\u03b1, receptor (FP). An example of a prostacyclin analog that is useful for the purposes of this invention is U-68,215 (see, e.g., J Pharmacol Exp Ther. 1992 March; 260(3):1023-7). In a preferred embodiment, the prostaglandin agonist is a compound that bind to the PGI<sub>2 </sub>receptor (IP) and/or the PGE<sub>2 </sub>receptors (EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3 </sub>and EP<sub>4</sub>). Certain prostaglandin agonists are disclosed in GB 1478281, GB1479156 and U.S. Pat. Nos. 4,175,203, 4,055,596, 4,175,203, 3,987,091, 3,991,106, 6,498,172 and Pharmacol Ther. 2004 103, 147-66 (all of which are incorporated herein by reference). Examples of prostaglandin agonists useful for the purposes of this invention include, but are not limited to, U46619, I-BOP and STA<sub>2 </sub>(agonists of TXA<sub>2</sub>), BW245C, L-644698, ZK110841, 13,15-dihydro-5-keto-PGD<sub>2</sub>, indomethacin, 15-R-methyl-PGD<sub>2</sub>, 15d-PGJ<sub>2 </sub>(agonists of PGD<sub>2</sub>), ONO-KI-004, iloprost, 17-phenyl-trinor PGE<sub>2</sub>, sulprostone, butaprost, 11-deoxy PGE<sub>1</sub>, AH13205, ONO-AEI-259, sulprostone, MB28767, misoprostol, SC46275, ONO-AE-249, PGE<sub>1</sub>-OH, and ONO-AEI-329 (PGE<sub>2 </sub>agonists), iloprost, cicaprost and carbacyclin, (agonists of PGI<sub>2</sub>), fluprostenol and latanoprost (agonists of PGF<sub>2\u03b1</sub>), as well as travoprost, bimatoprost, beraprost, carbacyclin, cloprostenol sodium, eicosopentanoic acid, docosohexanoic acid, ceramide, sodium butyrate and aluminum fluoride. Preferred prostaglandin agonists of the invention include agonists of PGI<sub>2 </sub>and PGE<sub>2</sub>. Particularly preferred prostaglandin agonists of the invention are agonists of PGI<sub>2</sub>.</p>\u201cAgonist\u201d refers to a molecule such as a compound, a drug, an enzyme activator or a hormone that enhances the activity of another molecule or receptor site.</p>\u201cNSAID-associated diseases and disorders\u201d refers to any disease, disorder or condition that may be treated in a subject in need thereof with NSAID administration. Examples of NSAID-associated diseases and disorders include, but are not limited to, pain and inflammation.</p>As used herein, the term \u201cpain\u201d includes all types of pain. Pain includes, but is not limited to, chronic pains, such as arthritis pain (e.g., pain associated with osteoarthritis and rheumatoid arthritis), neuropathic pain, and post-operative pain, chronic lower back pain, cluster headaches, herpes neuralgia, pha"
]